A poxvirus of primates. II. Immunology.
OrTeCa poxvirus shares antigens with Yaba virus, as evidenced by two-way crossreactions in complement-fixation and neutralization tests. Antibodies produced by vaccinia and monkeypox viruses showed weak complement-fixation reactions with OrTeCa viral antigen, but neutralization reactions were negative and cross protection in vivo was not demonstrated. OrTeCa and Yaba virus antisera both contained complement-fixing and neutralizing antibodies against swinepox virus, but swinepox antiserum had no antibodies to any other poxvirus. Long-lasting immunity to the OrTeCa pox disease was produced in monkeys and man by spontaneous infection or vaccination with OrTeCa poxvirus. Complement-fixing antibody titers could be measured in convalescence, but tended to drop to low levels or disappear thereafter. In contrast, neutralizing antibody titers remained high for 3 years, and monkeys that were challenged with OrTeCa virus were reFractory to a second infection.
Nicholas
A H
AH
Oregon Regional Primate Research Center, Beaverton, Oregon 97005, USA.
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D000956:Antigens, Viral / Q000276:immunology*; D002140:California; D002478:Cells, Cultured / Q000821:virology; D003168:Complement Fixation Tests; D006801:Humans; D008993:Monkeypox virus / Q000276:immunology; D009500:Neutralization Tests; D009922:Oregon; D011212:Poxviridae / Q000276:immunology*; D011213:Poxviridae Infections / Q000276:immunology*; D011323:Primates / Q000821:virology*; D018148:Suipoxvirus / Q000276:immunology; D013781:Texas; D014616:Vaccinia virus / Q000276:immunology; D014999:Yaba monkey tumor virus / Q000276:immunology
D000914:Antibodies, Viral; D000956:Antigens, Viral